Prognosis of refractory ascites in cirrhosis

##plugins.themes.academic_pro.article.sidebar##

Published Jul 20, 2016
Download
pdf
Vol. 94 No. 1 (2016): Issue Jan 2016

##plugins.themes.academic_pro.article.main##

Rym Ennaifer
Service de Gastro-entérologie Hôpital H. Thameur Tunis
Nour Elleuch
Hayfa Romdhane
Service de Gastro-entérologie A. Hôpital la Rabta. Tunis
Rania Hefaiedh
Maryem Cheikh
Sonda Chaabouni
Houda Ben Nejma
Najet Bel Hadj

Abstract

Background: Ascitic decompensation is a common major complication of cirrhosis and is associated with a poor outcome. In 5-10% of patients, ascites become resistant to treatment (either do not respond to a high dose of diuretics or because these drugs induce complications), which is called refractory ascites (RA). RA is associated with poor survival: 20-50% at 1 year. The aim of this study was to investigate the outcome of RA.
Methods: Retrospective study including consecutive cirrhotic patients admitted for controlling ascites between January 2010 and April 2013. Patients and cirrhosis characteristics were studied. Development of RA during follow-up was investigated. The impact of RA on the outcome (cirrhosis complications and survival) was evaluated.
Results: We included 124 cirrhotic patients: 59 females (47.6%); mean age was 58 years. Ascites was grade 3 in 38.5% and was the first episode in 45.1% of patients. Etiology of cirrhosis was mainly viral (57.3%). Child-Pugh score was B in 39.5% and C in 28.2%. Mean MELD score was 16 [6-40]. During follow-up, 27 patients developed RA, meaning a prevalence of 21.8%. RA type was diuretic intractable in all cases. Survival without complications was significantly reduced in patients with RA (4 vs 17 monthsp<10-3). RA was an independent predictive factor of global complications, spontaneous bacterial peritonitis and hepatic encephalopathy. Global survival was reduced in patients with RA (12 vs 16 months, p=0.069). One year survival was 45% for patients with RA vs 63% for other cirrhotics. In multivariate analysis, only Child-Pugh score, but not RA was an independent prognostic factor.
Conclusion: In this Tunisian sample we confirm that RA reduces survival and increases risk of cirrhosis complications, especially hepatic encephalopathy and spontaneous bacterial peritonitis. Therefore, these patients should be promptly listed for liver transplantation, over and above the MELD score.

Keywords:

Cirrhosis, Ascites, Prognosis

##plugins.themes.academic_pro.article.details##

References

  1. Moreau R, Lebrec D. Physiopathologie et pronostic de l'ascite réfractaire chez les malades atteints de cirrhose. Gastroentérologie Clin Biol. 2008;32:705-9.
  2. Arroyo V, Gins P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis.Hepatology. 1996;23:164-76.
  3. Runyon BA. AASLD PRACTICE GUIDELINE Management of Adult Patients with Ascites Due to Cirrhosis: Update 2012. Hepatology. 2013.
  4. Moreau R, Durand F, Lebrec D. L'ascite réfractaire chez les malades atteints de cirrhose. GastroentérologieClin Biol. 2008;32:703-4
  5. Stanley MM, Ochi S, Lee KK, Nemchausky BA, Greenlee HB, Allen JI, et al. Peritoneovenous Shunting as Compared with Medical Treatment in Patients with Alcoholic Cirrhosis and Massive Ascites. N Engl J Med. 1989;321:1632-8.
  6. Ginès P, Angeli P, Lenz K, Møller S, Moore K, Moreau R, et al. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53:397-417.
  7. Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646-9.
  8. Freeman R. The new liver allocation system: Moving toward evidence-based transplantation policy. LiverTranspl. 2002 Sep;8(9):851-8.
  9. Sersté T, Gustot T, Rautou P-E, Francoz C, Njimi H, Durand F, et al. Severe hyponatremia is a better predictor of mortality than MELDNa in patients with cirrhosis and refractory ascites. J Hepatol. 2012;57:274-80.
  10. Moore K. The management of ascites in cirrhosis: Report on the consensus conference of the International Ascites Club. Hepatology. 2003;38:258-66.
  11. Guevara M, Crdenas A, Urz J, Gins P. Prognosis of Patients with Cirrhosis and Ascites. In: Gins P, Arroyo V, Rods J, Schrier R, editors. Ascites and Renal Dysfunction in Liver Disease [Internet]. Oxford, UK: Blackwell Publishing Ltd; [cited 2013 Dec 19]. p. 260-70. Availablefrom: http://doi.wiley.com/10.1002/9780470987476.ch21
  12. Guevara M, Baccaro ME, Ríos J, Martín-Llahí M, Uriz J, Ruiz delArbol L, et al. Risk factors for hepatic encephalopathy in patients with cirrhosis and refractory ascites: relevance of serum sodium concentration: Risk factors for hepatic encephalopathy. Liver Int. 2010;30:1137-42.
  13. Salerno F, Guevara M, Bernardi M, Moreau R, Wong F, Angeli P, et al. Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis: Refractory ascites: pathogenesis, definition and therapy. Liver Int. 2010;30:937-47.
  14. Senousy B-E. Evaluation and management of patients with refractory ascites.World J Gastroenterol. 2009;15:67.
  15. Ginès P, Fernández-Esparrach G. Prognosis of cirrhosis with ascites. Ascites Ren Dysfunct Liver Dis PathogDiagn Treat Malden Mass Blackwell Sci. 1999;431-41.
  16. Salerno F, Borroni G, Moser P, Badalamenti S, Cassarà L, Maggi A, et al. Survival and prognostic factors of cirrhotic patients with ascites: a study of 134 outpatients. Am J Gastroenterol. 1993 Apr;88(4):514-9.
  17. Guardiola J, Baliellas C, Xiol X, Fernandez Esparrach G, Gines P, Ventura P, et al. External validation of a prognostic model for predicting survival of cirrhotic patients with refractory ascites1. Am J Gastroenterol. 2002 Sep;97(9):2374-8.
  18. Moreau R, Delegue P, Pessione F, Hillaire S, Durand F, Lebrec D, et al. Clinical characteristics and outcome of patients with cirrhosis and refractory ascites. Liver Int. 2004;24:457-64.
  19. Planas R, Montoliu S, Ballesté B, Rivera M, Miquel M, Masnou H, et al. Natural History of Patients Hospitalized for Management of Cirrhotic Ascites. ClinGastroenterolHepatol. 2006;4:1385-94.
  20. Durand F, Valla D. Assessment of the prognosis of cirrhosis: Child-Pugh versus MELD. J Hepatol. 2005;42:S100-107.
  21. Biggins SW, Rodriguez HJ, Bacchetti P, Bass NM, Roberts JP, Terrault NA. Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology. 2005;41:32-9.
  22. Kim WR, Biggins SW, Kremers WK, Wiesner RH, Kamath PS, Benson JT, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med. 2008;359:1018-26.
  23. Sersté T, Melot C, Francoz C, Durand F, Rautou P-E, Valla D, et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology. 2010;52:1017-22.
  24. Sersté T, Francoz C, Durand F, Rautou P-E, Melot C, Valla D, et al. Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: A cross-over study. J Hepatol. 2011;55:794-9.
  25. Ge PS, Runyon BA. The changing role of beta-blocker therapy in patients with cirrhosis.J Hepatol. 2014;60:643-53.
  26. Botta F. MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: a European study. Gut. 2003;52:134-9.